spacer
home > ebr > winter 2019 > monitoring malignancies through assay development
PUBLICATIONS
European Biopharmaceutical Review

Monitoring Malignancies Through Assay Development

Advances in the treatment of haematological malignancies through scientific discovery and innovation in drug development have dramatically improved both progression-free survival (PFS) and overall survival (OS) for blood cancers, including multiple myeloma and acute lymphoblastic leukaemia (ALL). In light of these continued improvements in clinical outcomes and survival rates, evaluating patients and assessing tumour burden at the time of diagnosis and monitoring disease progression throughout treatment and remission is important.

One method to assess tumour burden in lymphoid cancers is to determine minimal residual disease (MRD) or, perhaps, more appropriately referred to as measurable residual disease. MRD refers to the remaining number of cancer cells (ie, malignant B- or T-cells) that are present in a patient’s body during and after treatment and may eventually lead to recurrence of the disease. These residual cells can be present at very low levels, undetectable by traditional morphologic methods, such as microscopic examination of blood or a bone marrow or lymph node biopsy and require highly sensitive tests to be identified.

MRD in Lymphoid Cancers

Studies have shown that the presence of MRD is one of the strongest predictors of a patient’s long-term clinical outcome (1-2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ilan Kirsch received his MD from Harvard University Medical School, US, and, subsequently, completed his residency at Children’s Hospital Medical Center, US, and his fellowship in paediatric haematology/ oncology at the National Cancer Institute. He also completed a three-year postdoctoral fellowship in molecular genetics in the laboratory of Dr Philip Leder at the National Institute of Child Health and Human Development. Ilan currently serves as the Senior Vice President of Translational Medicine at Adaptive Biotechnologies and is an author of more than 160 peer-reviewed manuscripts and over 30 books, chapters, and reviews.
spacer
Ilan Kirsch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Prince Helps Sustainable Pharma Packaging Pioneers Woolcool Celebrate 10th Anniversary

Ground-breaking sustainable pharma packaging firm Woolcool celebrated a decade of innovation with a visit by HRH The Prince of Wales.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement